Plasminogen Therapy for Hyaline Membrane Lung Dysfunction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for lung dysfunction associated with hyaline membrane formation, such as respiratory distress syndrome, are limited in efficacy and often carry severe side effects, with insufficient consideration given to plasminogen levels in patients.
Innovation Solution
Administering plasminogen, optionally with a plasminogen activator, to treat or prevent lung dysfunction by reducing hyaline membrane formation and associated microthrombi.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for lung dysfunction are administered, then some therapeutic effect is achieved, but severe side effects occur and efficacy is limited
Solution Approach 1:
The patent changes the biochemical parameter of plasminogen levels in patients to treat lung dysfunction. By administering plasminogen to patients with deficient levels, the treatment addresses the root cause of hyaline membrane formation without the severe side effects of conventional therapies.
Solution Approach 2:
Plasminogen acts as an intermediary substance that converts to plasmin through plasminogen activators, indirectly breaking down fibrin in hyaline membranes. This intermediary mechanism provides therapeutic effect while avoiding direct harsh interventions on lung tissue.
2Reliability
If plasminogen is administered to patients, then lung function recovery is enhanced and hyaline membrane formation is reduced, but the treatment requires consideration of individual plasminogen levels
Solution Approach 1:
The treatment protocol monitors and adjusts plasminogen levels as a key parameter, administering plasminogen based on individual patient needs. This parameter-based approach improves lung function recovery while managing treatment complexity through targeted intervention.
3Reliability
If plasminogen and plasminogen activator are administered, then formation of microthrombi is reduced and lung function improves, but the mechanism requires understanding of fibrinolytic system dynamics
Solution Approach 1:
The treatment utilizes feedback from plasminogen level measurements and clinical response to adjust dosing of plasminogen and activators. This feedback mechanism reduces microthrombi formation effectively while managing the complexity of fibrinolytic system monitoring.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances lung function recovery and reduces the formation of hyaline membranes, improving oxygen saturation and preventing severe respiratory distress syndromes.
Implementation Method 1
plasminogen activator...reducing hyaline membrane formation...degrades fibrin in hyaline membranes and microthrombi
Data Source
AI summary
The present invention relates to plasminogen for use in a method for treating or preventing lung dysfunction associated with the formation of hyaline membranes in a patient, wherein the patient is preferably further administered with at least one plasminogen activator.